These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27241033)

  • 1. Combination of infliximab with thiopurines significantly reduces white cell and neutrophil counts in inflammatory bowel disease patients.
    Parihar V; Maceneaney O; Maguire S; Garry C; O'Sullivan M; Kennedy M; Safaya K; Smyth C; Farrell R
    Ir J Med Sci; 2017 May; 186(2):329-332. PubMed ID: 27241033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
    Luber RP; Dawson L; Munari S; Kariyawasam VC; Martin C; Gibson PR; Sparrow MP; Ward MG
    J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
    World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab.
    Sousa P; Patita M; Arroja B; Lago P; Rosa I; de Sousa HT; Ministro P; Mocanu I; Vieira A; Castela J; Moleiro J; Roseira J; Cancela E; Portela F; Correia L; Santiago M; Dias S; Alves C; Afonso J; Dias CC; Magro F
    Dig Liver Dis; 2024 May; 56(5):737-743. PubMed ID: 37980274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
    Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
    Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.
    Govani SM; Higgins PD
    J Crohns Colitis; 2010 Oct; 4(4):444-9. PubMed ID: 21122542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines.
    Bar-Yoseph H; Waterman M; Almog R; Billiet T; Vermeire S; Ungar B; Yanai H; Dotan I; Ben-Horin S; Chowers Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):69-75. PubMed ID: 27404966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent.
    Polakovicova V; Kadleckova B; Lucenicova J; Otottova K; Kinova S; Mikus P; Zelinkova Z
    Dig Liver Dis; 2019 Aug; 51(8):1112-1116. PubMed ID: 31147215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
    de Boer NKH; Peyrin-Biroulet L; Jharap B; Sanderson JD; Meijer B; Atreya I; Barclay ML; Colombel JF; Lopez A; Beaugerie L; Marinaki AM; van Bodegraven AA; Neurath MF
    J Crohns Colitis; 2018 Apr; 12(5):610-620. PubMed ID: 29293971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
    Drobne D; Kurent T; Golob S; Švegl P; Rajar P; Hanžel J; Koželj M; Novak G; Smrekar N; Ferkolj I; Štabuc B
    Aliment Pharmacol Ther; 2019 Apr; 49(7):880-889. PubMed ID: 30784100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
    Roblin X; Boschetti G; Williet N; Nancey S; Marotte H; Berger A; Phelip JM; Peyrin-Biroulet L; Colombel JF; Del Tedesco E; Paul S; Flourie B
    Aliment Pharmacol Ther; 2017 Jul; 46(2):142-149. PubMed ID: 28449228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
    Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
    Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
    Jharap B; Seinen ML; de Boer NK; van Ginkel JR; Linskens RK; Kneppelhout JC; Mulder CJ; van Bodegraven AA
    Inflamm Bowel Dis; 2010 Sep; 16(9):1541-9. PubMed ID: 20155846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.
    Axelrad JE; Roy A; Lawlor G; Korelitz B; Lichtiger S
    World J Gastroenterol; 2016 Dec; 22(46):10103-10117. PubMed ID: 28028358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease.
    Lord JD; Shows DM
    World J Gastroenterol; 2017 May; 23(18):3240-3251. PubMed ID: 28566883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.
    Barnes EL; Goldin A; Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
    Dig Dis Sci; 2016 Nov; 61(11):3261-3269. PubMed ID: 27639871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease.
    Phillips J; Leary S; Tyrrell-Price J
    BMJ Open Gastroenterol; 2023 Jun; 10(1):. PubMed ID: 37328288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.